Delmitide (RDP58) acetate is an orally active d-isomer decapeptide with potent anti-inflammatory activity.
| Molecular Weight | 1288.62 |
| Formula | C59H105N17O11.C2H4O2 |
| CAS Number | 501019-16-5 |
| Form | Solid |
| Solubility (25°C) | Water 6 mg/mL (Need ultrasonic) |
| Storage | Store at ≤ -20°C, protect from light, dry, sealed |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[1] M Bayés et al. Methods Find Exp Clin Pharmacol. Gateways to clinical trials
| Related Interferon-α/β/γ Products |
|---|
| IFN-γ Antagonist 1
IFN-γ Antagonist 1 (AYCRDGKIGPPKLDIRKEEKQI) is an antagonist of interferon γ (IFN γ). |
| IFN-γ Antagonist 1 acetate
IFN-γ Antagonist 1 (AYCRDGKIGPPKLDIRKEEKQI) acetate is an antagonist of interferon γ (IFN γ). |
| RO8191
RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent interferon (IFN) receptor agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and JAK/STAT phosphorylation. RO8191 shows antiviral activity against both HCV and EMCV with an IC50 of 200 nM for HCV replicon. RO8191 is a cccDNA modulator (CDM) through interferon-like activity and has anti-HBV activity. |
| IFN alpha-IFNAR-IN-1 hydrochloride
IFN alpha-IFNAR-IN-1 hydrochloride is a nonpeptidic, low-molecular-weight inhibitor of the interaction between IFN-α and IFNAR; inhibit MVA-induced IFN-α responses by BM-pDCs (IC50=2-8 uM). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
